Home / Market News / $GNPX

$GNPX news and market catalysts

The 5 most recent market catalysts affecting $GNPX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

5 catalysts 1 high impact 3 bullish 1 bearish Biotechnology
Nov 15, 2026 Corporate Catalyst Bearish Impact 92
Genprex Reports Third Quarter 2026 Financial Results
Genprex, Inc. released its third-quarter 2026 financial results, reporting zero revenue, which is consistent with the prior year. The company's operating losses widened significant…
Nov 5, 2026 Corporate Catalyst Bullish Impact 65
Genprex Identifies TROP2 as Potential Predictive Biomarker for REQORSA
Genprex announced research identifying TROP2 expression as a potential predictive biomarker for its lead drug candidate, REQORSA, in non-small cell lung cancer (NSCLC). This findin…
Oct 22, 2026 Corporate Catalyst Neutral Impact 55
Genprex Reports New Preclinical Data on TUSC2 Gene
Genprex reported new preclinical data on the TUSC2 gene, a component of their REQORSA® product candidate, highlighting its role in cellular function during brain aging. This matter…
Aug 18, 2026 Corporate Catalyst Bullish Impact 75
Genprex Announces Development And Manufacturing Agreement With Undisclosed U.S. CDMO To Scale Up cGMP Production Of Diabetes Gene Therapy For IND-Enabling Studies, Future Trials
This headline is a significant corporate catalyst for Genprex. Securing a CDMO for cGMP production is a critical de-risking event for any biotech company, especially one developing…
Aug 3, 2026 Corporate Catalyst Bullish Impact 65
Genprex Partners With Roche Diagnostics To Validate Biomarkers For Patient Selection In Clinical Trials For Non-Small Cell Lung Cancer
Genprex has announced a strategic partnership with Roche Diagnostics to validate TROP2 and PTEN as biomarkers for patient selection in their Non-Small Cell Lung Cancer (NSCLC) clin…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.